Related Experiment Videos

Troponin T measurement after myocardial infarction can identify left ventricular ejection of less than 40%

A C Rao1, P O Collinson, R Canepa-Anson

  • 1Department of Cardiology, Mayday University Hospital, Croydon, Surrey, UK.

Insights

Serum troponin T levels after myocardial infarction reliably identify patients with reduced left ventricular ejection fraction (<40%). This simple test predicts a poor prognosis, aiding in early risk stratification for acute myocardial infarction patients.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Diagnostic Imaging

Background:

  • Acute myocardial infarction (AMI) poses significant mortality risks.
  • Left ventricular ejection fraction (LVEF) is a key prognostic indicator post-AMI.
  • Accurate identification of patients with LVEF < 40% is crucial for timely intervention.

Purpose of the Study:

  • To evaluate serum troponin T (cTnT) as a non-invasive marker for identifying AMI patients with LVEF < 40%.
  • To correlate cTnT levels with angiographically determined LVEF in a post-MI cohort.
  • To assess the prognostic value of cTnT in predicting adverse outcomes in AMI.

Main Methods:

  • Prospective study of 50 consecutive patients admitted for their first AMI.
  • Measurement of serum troponin T concentrations within 12-48 hours of admission.
  • Performance of coronary angiography and left ventriculography to determine LVEF.

Main Results:

  • A strong negative correlation was observed between serum troponin T levels and LVEF (r = -0.72, p < 0.0001).
  • A troponin T concentration > 2.8 µg/L accurately predicted LVEF < 40% with 100% sensitivity and 92.9% specificity.
  • Receiver operator characteristic (ROC) curve analysis showed high diagnostic accuracy (Area Under Curve = 0.9773).

Conclusions:

  • Serum troponin T is a reliable, non-invasive, and cost-effective biomarker for identifying AMI patients with impaired LVEF (<40%).
  • Elevated troponin T levels identify patients at high risk for adverse prognosis following their first myocardial infarction.
  • This biomarker facilitates early risk stratification and guides clinical management decisions.
Abstract

Related Concept Videos